{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:43Z","timestamp":1790803603966,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06416-2","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:14:26Z","timestamp":1767968066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review"],"prefix":"10.1007","volume":"152","author":[{"given":"Tianyi","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"9","key":"6416_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00759-3","volume":"21","author":"M Alexander","year":"2020","unstructured":"Alexander M, Lin E, Cheng H (2020) Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations. Curr Treat Options Oncol 21(9):72. https:\/\/doi.org\/10.1007\/s11864-020-00759-3","journal-title":"Curr Treat Options Oncol"},{"key":"6416_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102605","volume":"120","author":"Q Bai","year":"2023","unstructured":"Bai Q, Wang J, Zhou X (2023) EGFR exon20 insertion mutations in non-small cell lung cancer: clinical implications and recent advances in targeted therapies. Cancer Treat Rev 120:102605. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102605","journal-title":"Cancer Treat Rev"},{"key":"6416_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13970","author":"D Barth\u00e9l\u00e9my","year":"2025","unstructured":"Barth\u00e9l\u00e9my D, Vigneron A, Rousset X, Guitton J, Grolleau E, Raffin M, Payen L (2025) Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon-19-deleted advanced NSCLC mutation. FEBS Open Bio. https:\/\/doi.org\/10.1002\/2211-5463.13970","journal-title":"FEBS Open Bio"},{"issue":"9","key":"6416_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/s1470-2045(10)70034-6","volume":"11","author":"P Beauchesne","year":"2010","unstructured":"Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11(9):871\u2013879. https:\/\/doi.org\/10.1016\/s1470-2045(10)70034-6","journal-title":"Lancet Oncol"},{"issue":"9","key":"6416_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29668","volume":"10","author":"DJH Bian","year":"2024","unstructured":"Bian DJH, Lazaratos AM, Maritan SM, Quaiattini A, Zeng Z, Zhu Z, Dankner M (2024) Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: a systematic review and meta-analysiss. Heliyon 10(9):e29668. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29668","journal-title":"Heliyon"},{"issue":"1","key":"6416_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/tlcr-24-1006","volume":"14","author":"M Bortolot","year":"2025","unstructured":"Bortolot M, Huijs JWJ, Brandsma D, Compter A, van Geel R, Hendriks LEL (2025) Advancing leptomeningeal metastases treatment in EGFR-mutated non-small cell lung cancer: lessons from the BLOSSOM trial. Transl Lung Cancer Res 14(1):7\u201313. https:\/\/doi.org\/10.21037\/tlcr-24-1006","journal-title":"Transl Lung Cancer Res"},{"key":"6416_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01224","volume":"9","author":"SM Buszek","year":"2019","unstructured":"Buszek SM, Chung C (2019) Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials. Front Oncol 9:1224. https:\/\/doi.org\/10.3389\/fonc.2019.01224","journal-title":"Front Oncol"},{"issue":"4","key":"6416_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","volume":"12","author":"E Castellanos","year":"2017","unstructured":"Castellanos E, Feld E, Horn L (2017) Driven by Mutations: the predictive value of mutation subtype in EGFR-Mutated non-small cell lung cancer. J Thorac Oncol 12(4):612\u2013623. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.014","journal-title":"J Thorac Oncol"},{"issue":"1","key":"6416_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","volume":"20","author":"H Chen","year":"2025","unstructured":"Chen H, Yang S, Wang L, Wu Y, Wu Y, Ma S, Wang Q (2025a) High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study. J Thorac Oncol 20(1):65\u201375. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1385","journal-title":"J Thorac Oncol"},{"key":"6416_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1632369","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen Y, Qin Z, Zhan L, Guo X, Fukuda K, Zhou Q (2025b) Case report: extended survival in KRAS-G12V NSCLC with leptomeningeal metastasis through integrated intrathecal chemotherapy and systemic therapies. Front Pharmacol 16:1632369","journal-title":"Front Pharmacol"},{"issue":"2","key":"6416_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3171\/2022.11.Jns221888","volume":"139","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Yang HC, Luo YH, Chen CJ, Wu HM, Chen YM, Lee CC (2023) Leptomeningeal metastasis in patients with non-small cell lung cancer after stereotactic radiosurgery for brain metastasis. J Neurosurg 139(2):385\u2013392. https:\/\/doi.org\/10.3171\/2022.11.Jns221888","journal-title":"J Neurosurg"},{"key":"6416_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"6","author":"G da Cunha Santos","year":"2011","unstructured":"da Cunha Santos G, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6:49\u201369. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130206","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"6416_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.21037\/tlcr.2016.12.06","volume":"5","author":"P Economopoulou","year":"2016","unstructured":"Economopoulou P, Mountzios G (2016) Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. Transl Lung Cancer Res 5(6):588\u2013598. https:\/\/doi.org\/10.21037\/tlcr.2016.12.06","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"6416_CR14","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T (2021) Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1\/2 clinical trial (Unique Identifier: ChiCTR1800016615). J Thorac Oncol 16(8):1359\u20131368. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"6416_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102384","volume":"9","author":"C Fan","year":"2024","unstructured":"Fan C, Jiang Z, Teng C, Song X, Li L, Shen W, Jiang Q, Huang D, Lv Y, Du L, Wang G, Hu Y, Man S, Zhang Z, Gao N, Wang F, Shi T, Xin T (2024) Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial. ESMO Open 9(4):102384. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102384","journal-title":"ESMO Open"},{"key":"6416_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"6416_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2021.04.002","volume":"11","author":"A Garsa","year":"2021","unstructured":"Garsa A, Jang JK, Baxi S, Chen C, Akinniranye O, Hall O, Larkin J, Motala A, Hempel S (2021) Radiation therapy for brain metastases: a systematic review. Pract Radiat Oncol 11(5):354\u2013365. https:\/\/doi.org\/10.1016\/j.prro.2021.04.002","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"6416_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","volume":"8","author":"HS Gwak","year":"2013","unstructured":"Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Lee SH (2013) Analysis of treatment outcomes of IVC in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 8(5):599\u2013605. https:\/\/doi.org\/10.1097\/JTO.0b013e318287c943","journal-title":"J Thorac Oncol"},{"key":"6416_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"PT Harrison","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 61:167\u2013179. https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.015","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"6416_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.21037\/tlcr-24-477","volume":"13","author":"X Ji","year":"2024","unstructured":"Ji X, Jiang R, Liu T, Provencio M, Lee SC, Zhan Q, Zhou X (2024) Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations. Transl Lung Cancer Res 13(7):1695\u20131707. https:\/\/doi.org\/10.21037\/tlcr-24-477","journal-title":"Transl Lung Cancer Res"},{"key":"6416_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101832","volume":"39","author":"C Jia","year":"2024","unstructured":"Jia C, Xu Q, Zhao L, Kong F, Jia Y (2024) Therapeutic role of EGFR - tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis. Transl Oncol 39:101832. https:\/\/doi.org\/10.1016\/j.tranon.2023.101832","journal-title":"Transl Oncol"},{"key":"6416_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf006","author":"N Kanaya","year":"2025","unstructured":"Kanaya N, Seddiq W, Chen KS, Kajiwara Y, Moreno Lama L, Borges P, Shah K (2025) Engineered allogeneic stem cells orchestrate T lymphocyte driven immunotherapy in immunosuppressive leptomeningeal brain metastasis. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djaf006","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6416_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10585-021-10120-z","volume":"39","author":"SP Leong","year":"2022","unstructured":"Leong SP, Naxerova K, Keller L, Pantel K, Witte M (2022) Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clin Exp Metastasis 39(1):159\u2013179. https:\/\/doi.org\/10.1007\/s10585-021-10120-z","journal-title":"Clin Exp Metastasis"},{"issue":"11","key":"6416_CR24","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Wu YL (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11(11):1962\u20131969. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","journal-title":"J Thorac Oncol"},{"issue":"10","key":"6416_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20690","volume":"9","author":"G Li","year":"2023","unstructured":"Li G, Fang M, Zhou Y, Liu X, Tian P, Mei F (2023) Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R\/T790M or L858R\/S768I mutations: two case reports. Heliyon 9(10):e20690. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20690","journal-title":"Heliyon"},{"issue":"8","key":"6416_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114613","volume":"43","author":"YS Li","year":"2024","unstructured":"Li YS, Lai WP, Yin K, Zheng MM, Tu HY, Guo WB, Wu YL (2024) Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC. Cell Rep 43(8):114613. https:\/\/doi.org\/10.1016\/j.celrep.2024.114613","journal-title":"Cell Rep"},{"key":"6416_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101113","volume":"60","author":"SK Liang","year":"2025","unstructured":"Liang SK, Liao WY, Shih JY, Hsu CL, Yang CY, Wu SG, Yu CJ (2025) Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis. Neoplasia 60:101113. https:\/\/doi.org\/10.1016\/j.neo.2024.101113","journal-title":"Neoplasia"},{"key":"6416_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1322635","volume":"13","author":"X Liu","year":"2023","unstructured":"Liu X, Mei F, Fang M, Jia Y, Zhou Y, Li C, Li G (2023) Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases. Front Oncol 13:1322635. https:\/\/doi.org\/10.3389\/fonc.2023.1322635","journal-title":"Front Oncol"},{"issue":"2","key":"6416_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1759-7714.13738","volume":"12","author":"ZQ Lu","year":"2021","unstructured":"Lu ZQ, Cai J, Wang X, Wei JP, Zeng ZM, Huang L, Liu AW (2021) Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: a phase II single-arm prospective clinical trial. Thorac Cancer 12(2):172\u2013180. https:\/\/doi.org\/10.1111\/1759-7714.13738","journal-title":"Thorac Cancer"},{"issue":"3","key":"6416_CR30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11060-023-04520-2","volume":"165","author":"Q Miao","year":"2023","unstructured":"Miao Q, Zheng X, Li L, Zheng X, Zhang L, Jiang K, Lin G (2023) Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer. J Neurooncol 165(3):517\u2013525. https:\/\/doi.org\/10.1007\/s11060-023-04520-2","journal-title":"J Neurooncol"},{"issue":"2","key":"6416_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","volume":"7","author":"PG Morris","year":"2012","unstructured":"Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Omuro AM (2012) Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 7(2):382\u2013385. https:\/\/doi.org\/10.1097\/JTO.0b013e3182398e4f","journal-title":"J Thorac Oncol"},{"issue":"3","key":"6416_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11060-024-04616-3","volume":"167","author":"K Nakagawa","year":"2024","unstructured":"Nakagawa K, Takano K, Nishino K, Ohe S, Nakayama T, Arita H (2024) Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers. J Neurooncol 167(3):397\u2013406. https:\/\/doi.org\/10.1007\/s11060-024-04616-3","journal-title":"J Neurooncol"},{"issue":"5","key":"6416_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10585-023-10225-7","volume":"40","author":"H Oyoshi","year":"2023","unstructured":"Oyoshi H, Hirata H, Hirano Y, Zenda S, Zhou Y, Tomizawa K, Fujisawa T, Nakamura M, Hojo H, Motegi A, Kageyama S-I, Zenke Y, Goto K, Ishihara S, Naganawa S, Akimoto T (2023) Prognostic impact of EGFR\/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy. Clin Exp Metastasis 40(5):407\u2013413. https:\/\/doi.org\/10.1007\/s10585-023-10225-7","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"6416_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.Ccr-22-1585","volume":"29","author":"G Ozcan","year":"2023","unstructured":"Ozcan G, Singh M, Vredenburgh JJ (2023) Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments. Clin Cancer Res 29(1):11\u201329. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1585","journal-title":"Clin Cancer Res"},{"issue":"23","key":"6416_CR35","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/jco.24.00708","volume":"42","author":"S Park","year":"2024","unstructured":"Park S, Baldry R, Jung HA, Sun JM, Lee SH, Ahn JS, Kim YJ, Lee Y, Kim D-W, Kim S-W, Lee KH, Lee WJ, Choi JW, Chong K, Lee J-I, Gwon S-H, Son N-H, Ahn MJ (2024) Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM). J Clin Oncol 42(23):2747\u20132756. https:\/\/doi.org\/10.1200\/jco.24.00708","journal-title":"J Clin Oncol"},{"key":"6416_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.4103\/ijc.IJC_74_19","volume":"56","author":"S Patil","year":"2019","unstructured":"Patil S, Rathnum KK (2019) Management of leptomeningeal metastases in non-small cell lung cancer. Indian J Cancer 56:S1-s9. https:\/\/doi.org\/10.4103\/ijc.IJC_74_19","journal-title":"Indian J Cancer"},{"issue":"7","key":"6416_CR37","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.21037\/jtd-23-841","volume":"15","author":"Z Qin","year":"2023","unstructured":"Qin Z, Zhang H, Yan P, Yu L, Hong C, Calvetti L, Passaro A, Araujo A, Chen Y (2023) Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report. J Thorac Dis 15(7):4016\u20134026. https:\/\/doi.org\/10.21037\/jtd-23-841","journal-title":"J Thorac Dis"},{"issue":"1","key":"6416_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin M-C, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"issue":"1","key":"6416_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00006123-200007000-00011","volume":"47","author":"DI Sandberg","year":"2000","unstructured":"Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47(1):49\u201354. https:\/\/doi.org\/10.1097\/00006123-200007000-00011","journal-title":"Neurosurgery"},{"issue":"9","key":"6416_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"6416_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1903827","volume":"18","author":"L Tagliaferri","year":"2022","unstructured":"Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Cas\u00e0 C, Di Stefani A, Pagliara MM, D\u2019Aviero A, Schinzari G, Chiesa S, Mazzarella C, Manfrida S, Colloca GF, Marazzi F, Morganti AG, Blasi MA, Peris K, Tortora G, Valentini V (2022) Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother 18(3):1903827. https:\/\/doi.org\/10.1080\/21645515.2021.1903827","journal-title":"Hum Vaccin Immunother"},{"key":"6416_CR42","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4427-24","author":"H Tomizawa","year":"2024","unstructured":"Tomizawa H, Mouri A, Mikoshiba S, Tsukamoto K, Abe Y, Oda M, Kamimura M (2024) Alternating administration of Osimertinib for Leptomeningitis and docetaxel plus Ramucirumab for lung adenocarcinoma resistant to epidermal growth factor receptor tyrosine kinase inhibitors: a case report. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.4427-24","journal-title":"Intern Med"},{"issue":"12","key":"6416_CR43","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/neuonc\/noae138","volume":"26","author":"JWT van der Wel","year":"2024","unstructured":"van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, Compter A, Boltjes RPB, Sol N, Monkhorst K, van den Broek D, Smit EF, de Langen AJ, Brandsma D (2024) Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: osimertinib resistance analysis-leptomeningeal metastases study. Neuro Oncol 26(12):2316\u20132327. https:\/\/doi.org\/10.1093\/neuonc\/noae138","journal-title":"Neuro Oncol"},{"key":"6416_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115377","volume":"220","author":"E van Kessel","year":"2025","unstructured":"van Kessel E, Woerdman N, Pluim D, Kerklaan BM, van den Broek D, Huitema ADR, Brandsma D (2025) Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors. Eur J Cancer 220:115377. https:\/\/doi.org\/10.1016\/j.ejca.2025.115377","journal-title":"Eur J Cancer"},{"key":"6416_CR45","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11060-016-2199-5","volume":"129","author":"C Vinayanuwattikun","year":"2016","unstructured":"Vinayanuwattikun C, Mingmalairak S, Jittapiromsak N, Thaipisuttikul I, Sriuranpong V, Mutirangura A, Shuangshoti S (2016) SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis). J Neuro-Oncol 129:395\u2013403","journal-title":"J Neuro-Oncol"},{"key":"6416_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.09.013","volume":"174","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang X, Li NJ, Xue JX (2022) Leptomeningeal metastases in non-small cell lung cancer: diagnosis and treatment. Lung Cancer 174:1\u201313. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.013","journal-title":"Lung Cancer"},{"key":"6416_CR47","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","volume":"26","author":"JA Wilcox","year":"2024","unstructured":"Wilcox JA, Chukwueke UN, Ahn M-J, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P, Garzia L, Glantz M, Glitza Oliva IC, Kumthekar P, Le Rhun E, Nagpal S, O\u2019Brien B, Pentsova E, Quant Lee E, Remsik J, Rud\u00e0 R, Smalley I, Taylor MD, Weller M, Wefel J, Yang JT, Young RJ, Wen PY, Boire AA (2024) Leptomeningeal metastases from solid tumors: a Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions. Neuro Oncol 26:1781\u20131804","journal-title":"Neuro Oncol"},{"issue":"1","key":"6416_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad018","volume":"5","author":"P Wong","year":"2023","unstructured":"Wong P, Masucci L, Florescu M, Plourde ME, Panet-Raymond V, Pavic M, Owen S, Masson-Cot\u00e9 L, M\u00e9nard C, Routy B, Tehfe M, Nelson K, Guilbert F, Boucher O, Keshavarzi S, Blais N, Roberge D (2023) Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. Neuro-Oncol Adv 5(1):vdad018. https:\/\/doi.org\/10.1093\/noajnl\/vdad018","journal-title":"Neuro-Oncol Adv"},{"key":"6416_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.01.007","author":"WKY Wong","year":"2025","unstructured":"Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC (2025) CNS outcomes of osimertinib plus chemotherapy in patients with EGFR mutation positive lung cancer beyond osimertinib progression. Clin Lung Cancer. https:\/\/doi.org\/10.1016\/j.cllc.2025.01.007","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"6416_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38. https:\/\/doi.org\/10.1186\/s12943-018-0777-1","journal-title":"Mol Cancer"},{"issue":"2","key":"6416_CR51","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3892\/ol.2016.4783","volume":"12","author":"YL Wu","year":"2016","unstructured":"Wu YL, Zhou L, Lu Y (2016) Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis. Oncol Lett 12(2):1301\u20131314. https:\/\/doi.org\/10.3892\/ol.2016.4783","journal-title":"Oncol Lett"},{"key":"6416_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107475","volume":"188","author":"H Wu","year":"2024","unstructured":"Wu H, Zhang Q, Zhai W, Chen Y, Yang Y, Xie M, Huang Z, Xu Y, Li H, Gong L, Yu S, Fan Y, Chen K (2024a) Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis. Lung Cancer 188:107475. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107475","journal-title":"Lung Cancer"},{"issue":"4","key":"6416_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2024.02.001","volume":"25","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhao Y, Wu Y, Chen H, Ma S, Wang Q (2024b) A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis. Clin Lung Cancer 25(4):347-353.e341. https:\/\/doi.org\/10.1016\/j.cllc.2024.02.001","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"6416_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10676-x","volume":"23","author":"Z Xu","year":"2023","unstructured":"Xu Z, Hao X, Wang Q, Yang K, Li J, Xing P (2023) Intracranial efficacy and safety of furmonertinib 160\u2009mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy. BMC Cancer 23(1):206. https:\/\/doi.org\/10.1186\/s12885-023-10676-x","journal-title":"BMC Cancer"},{"issue":"1","key":"6416_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04134-7","volume":"23","author":"Q Xu","year":"2025","unstructured":"Xu Q, Huang K, Tong L, Yan D, Zhao Y, Yang H, Jin W, Zhang L, Cai J, Chen Q (2025) Intrathecal pemetrexed efficacy and cerebrospinal fluid tumor marker response in refractory leptomeningeal metastasis of non-small-cell lung cancer: a single-arm phase II trial. BMC Med 23(1):301. https:\/\/doi.org\/10.1186\/s12916-025-04134-7","journal-title":"BMC Med"},{"issue":"33","key":"6416_CR56","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/jco.22.01148","volume":"40","author":"JT Yang","year":"2022","unstructured":"Yang JT, Wijetunga NA, Pentsova E, Wolden S, Young RJ, Correa D, Zhang Z, Zheng J, Steckler A, Bucwinska W, Bernstein A, Betof Warner A, Yu H, Kris MG, Seidman AD, Wilcox JA, Malani R, Lin A, DeAngelis LM, Lee NY, Powell SN, Boire A (2022) Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J Clin Oncol 40(33):3858\u20133867. https:\/\/doi.org\/10.1200\/jco.22.01148","journal-title":"J Clin Oncol"},{"issue":"45","key":"6416_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000040320","volume":"103","author":"L Yao","year":"2024","unstructured":"Yao L, Zhang C, Li D, Xu L, Yang X (2024) Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 103(45):e40320. https:\/\/doi.org\/10.1097\/md.0000000000040320","journal-title":"Medicine (Baltimore)"},{"issue":"216","key":"6416_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007205","volume":"5","author":"H Yasuda","year":"2013","unstructured":"Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB (2013) Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5(216):216ra177. https:\/\/doi.org\/10.1126\/scitranslmed.3007205","journal-title":"Sci Transl Med"},{"issue":"1","key":"6416_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03331-9","volume":"20","author":"Y Yi","year":"2022","unstructured":"Yi Y, Cai J, Xu P, Xiong L, Lu Z, Zeng Z, Liu A (2022) Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer. J Transl Med 20(1):122. https:\/\/doi.org\/10.1186\/s12967-022-03331-9","journal-title":"J Transl Med"},{"issue":"1","key":"6416_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11060-024-04716-0","volume":"169","author":"C Yu","year":"2024","unstructured":"Yu C, Xu T, Fang H, Wang X, Liu N, Yang L, Fang S (2024) High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer. J Neurooncol 169(1):203\u2013213. https:\/\/doi.org\/10.1007\/s11060-024-04716-0","journal-title":"J Neurooncol"},{"issue":"1","key":"6416_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2873-2","volume":"5","author":"X Yufen","year":"2016","unstructured":"Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y (2016) The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus 5(1):1244. https:\/\/doi.org\/10.1186\/s40064-016-2873-2","journal-title":"Springerplus"},{"issue":"1","key":"6416_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01627-y","volume":"15","author":"J Zhen","year":"2020","unstructured":"Zhen J, Wen L, Lai M, Zhou Z, Shan C, Li S, Lin T, Wu J, Wang W, Xu S, Liu D, Lu M, Zhu D, Chen L, Cai L, Zhou C (2020) Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol 15(1):185. https:\/\/doi.org\/10.1186\/s13014-020-01627-y","journal-title":"Radiat Oncol"},{"issue":"2","key":"6416_CR63","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jtho.2020.10.008","volume":"16","author":"MM Zheng","year":"2021","unstructured":"Zheng MM, Li YS, Tu HY, Jiang BY, Yang JJ, Zhou Q, Xu CR, Yang XR, Wu YL (2021) Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC. J Thorac Oncol 16(2):250\u2013258. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.008","journal-title":"J Thorac Oncol"},{"key":"6416_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1377451","volume":"14","author":"W Zhong","year":"2024","unstructured":"Zhong W, Wu L, Huang L, Wang J, Shi H, Wu S (2024) Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review. Front Oncol 14:1377451. https:\/\/doi.org\/10.3389\/fonc.2024.1377451","journal-title":"Front Oncol"},{"issue":"1","key":"6416_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10806-5","volume":"23","author":"T Zhou","year":"2023","unstructured":"Zhou T, Zhu S, Xiong Q, Gan J, Wei J, Cai J, Liu A (2023) Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study. BMC Cancer 23(1):333. https:\/\/doi.org\/10.1186\/s12885-023-10806-5","journal-title":"BMC Cancer"},{"key":"6416_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-04938-w","author":"L Zhuang","year":"2025","unstructured":"Zhuang L, Yin X, Liu X, Liu D, Wei Z, Chen Y, Zhao K, Li Y, Yu J, Meng X (2025) Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single\u2011center retrospective study. J Neurooncol. https:\/\/doi.org\/10.1007\/s11060-025-04938-w","journal-title":"J Neurooncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06416-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06416-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06416-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:06:36Z","timestamp":1768165596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06416-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6416"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06416-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"38"}}